Loading...
Study Overview: This dashboard visualizes extracted Quality of Life (QoL) outcomes from the MONALEESA-3 trial. The study compares Ribociclib + Fulvestrant vs. Placebo + Fulvestrant in HR+/HER2- advanced breast cancer. Key findings indicate that adding Ribociclib maintains QoL while delaying deterioration in physical functioning and pain.
Study Design & Arms
Comparison of patient cohorts and interventions (N values extracted from methods).
Baseline EORTC QLQ-C30 Scores
Comparison of mean baseline Global Health Status scores (Mean ± SD). Higher is better.
Time to Deterioration (Hazard Ratios)
Hazard Ratios for TTD ≥10% (Lower is better). Error bars represent 95% CI. Dashed line at 1.0 (no difference).
Mean Time to Deterioration (Physical Functioning)
Mean months until ≥10% deterioration in Physical Functioning score (M03). Higher is better.
Metric Landscape
Overview of all extracted metrics, their polarity (Higher/Lower Better), and values.
Evidence Provenance Map
Mapping metrics to their source locations in the document.
Appendix: Raw Data & Sources
| ID | Metric Name | Group | Value | Unit | Source |
|---|
Limits: